Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.

Abstract: A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier.

Abstract: A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier.

Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.

Abstract: A game that is played following the same rules most football fans will understand. It consists of a playing board (measuring 36?×60?) that resembles a football field, with the yardage clearly marked (every 5 inches represents 10 yards) and a goal post at each end, a coin for decision making, twenty offense and twenty defense cards representing the teams, one set of red dice, one set of blue dice, a challenge flag, one challenge dice (with 3 sides for stand and 3 sides for overturned) and a play clock. The game is played with four six-minute quarters. The clock has multiple buttons to control the following: adjusting the game clock, adjusting each team's time-outs, adjusting each team's challenges, adjusting the score for each team.

Abstract: A method of manufacturing a tampon includes transporting a web of material in a machine direction. The web of material has a base web and an absorbent web. The absorbent web has a free end and a bonded end wherein the bonded end is bonded to the base web. The free end of the absorbent web is moved in spaced relationship with the base web. The base web is bonded to a substrate.

Abstract: A method of manufacturing a tampon generally comprises forming a softwind including a core and a cover overlying and at least in part covering the core. The cover carries an absorbent web having a free end and a bonded end wherein the free end is capable of moving relative to the cover. The softwind is passed through a transfer assist device to facilitate the transferring of the free end of the absorbent web without the absorbent web becoming misaligned relative to the cover.

Abstract: A method of manufacturing a tampon includes transporting a web of material in a machine direction. The web of material has a base web and an absorbent web. The absorbent web has a free end and a bonded end wherein the bonded end is bonded to the base web. At least the free end of the absorbent web of the web to is controlled to inhibit movement of the absorbent web relative to the base web. The web of material is cut into discrete web segments while controlling at least the free end of the absorbent web. The discrete web segments is bonded to a substrate.

Abstract: A method of manufacturing a tampon generally comprises forming a softwind including a core and a cover overlying and at least in part covering the core. The cover carries an absorbent web having a free end and a bonded end wherein the free end is capable of moving relative to the cover. The softwind is passed through a transfer assist device to facilitate the transferring of the free end of the absorbent web without the absorbent web becoming misaligned relative to the cover.

Abstract: A method of manufacturing a tampon includes transporting a web of material in a machine direction. The web of material has a base web and an absorbent web. The absorbent web has a free end and a bonded end wherein the bonded end is bonded to the base web. The free end of the absorbent web is moved in spaced relationship with the base web. The base web is bonded to a substrate.

Abstract: A method of manufacturing a tampon comprises the steps of at least partially overlaying a web of base material with a web of absorbent material. The web of absorbent material is secured to the web of base material with a first securement. At least one of the web of base material and the web of absorbent material is folded after the first securement. The web of absorbent material is further secured to the web of base material with a second securement that is a stronger securement than the first securement. The web of absorbent material and the web of base material together define a web of cover material. The web of cover material is applied to an absorbent structure. The web of cover material and the absorbent structure is manipulated such that the web of cover material extends about a circumference of the absorbent structure to form a tampon.

Abstract: A method of manufacturing a tampon includes transporting a web of material in a machine direction. The web of material has a base web and an absorbent web. The absorbent web has a free end and a bonded end wherein the bonded end is bonded to the base web. At least the free end of the absorbent web of the web to is controlled to inhibit movement of the absorbent web relative to the base web. The web of material is cut into discrete web segments while controlling at least the free end of the absorbent web. The discrete web segments is bonded to a substrate.

Abstract: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.

Abstract: Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in ovarian cancer. In preferred embodiments, the body sample is a serum sample. The biomarkers of the invention include any genes or proteins that are selectively overexpressed in ovarian cancer, including, for example, acute phase reactants, lipoproteins, proteins involved in the regulation of the complement system, regulators of apoptosis, proteins that bind hemoglobin, heme, or iron, cytostructural proteins, enzymes that detoxify metabolic byproducts, growth factors, and hormone transporters. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques.